LT3675826T - Katijoninės lipidų kompozicijos audiniams-specifiniam įterpimui - Google Patents
Katijoninės lipidų kompozicijos audiniams-specifiniam įterpimuiInfo
- Publication number
- LT3675826T LT3675826T LTEPPCT/US2018/042555T LTUS2018042555T LT3675826T LT 3675826 T LT3675826 T LT 3675826T LT US2018042555 T LTUS2018042555 T LT US2018042555T LT 3675826 T LT3675826 T LT 3675826T
- Authority
- LT
- Lithuania
- Prior art keywords
- tissue
- cationic lipid
- lipid compositions
- specific insertion
- specific
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762552783P | 2017-08-31 | 2017-08-31 | |
| PCT/US2018/042555 WO2019045897A1 (en) | 2017-08-31 | 2018-07-17 | CATIONIC LIPIDIC COMPOSITIONS FOR TISSUE-SPECIFIC ADMINISTRATION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3675826T true LT3675826T (lt) | 2023-09-11 |
Family
ID=63104088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2018/042555T LT3675826T (lt) | 2017-08-31 | 2018-07-17 | Katijoninės lipidų kompozicijos audiniams-specifiniam įterpimui |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20190060482A1 (enExample) |
| EP (1) | EP3675826B1 (enExample) |
| JP (2) | JP7379325B2 (enExample) |
| CN (1) | CN111065377A (enExample) |
| AU (1) | AU2018324345B2 (enExample) |
| CA (1) | CA3073851A1 (enExample) |
| LT (1) | LT3675826T (enExample) |
| WO (1) | WO2019045897A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11690921B2 (en) * | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
| MA69005B1 (fr) | 2019-04-16 | 2025-01-31 | Genfit | Compositions et procédés pour la stabilisation de micro-arn |
| CA3145425A1 (en) * | 2019-07-03 | 2021-01-07 | Factor Bioscience Inc. | Cationic lipids and uses thereof |
| US10501404B1 (en) | 2019-07-30 | 2019-12-10 | Factor Bioscience Inc. | Cationic lipids and transfection methods |
| EP3865122A1 (en) * | 2020-02-11 | 2021-08-18 | Pantherna Therapeutics GmbH | Lipid composition and use thereof for delivery of a therapeutically active agent to endothelium |
| CN117750948A (zh) * | 2021-03-23 | 2024-03-22 | 瑞科德治疗公司 | 用于靶向全身性递送至细胞的组合物和方法 |
| EP4547282A1 (en) * | 2022-06-30 | 2025-05-07 | Life Technologies Corporation | Lipid compositions for in vivo delivery |
| CN120615011A (zh) | 2022-12-29 | 2025-09-09 | 生命科技股份有限公司 | 脂质组合物及用于递送到免疫细胞的方法 |
| WO2024250133A1 (zh) * | 2023-06-05 | 2024-12-12 | 安徽医科大学第一附属医院 | 肺靶向纳米胶束、制备方法及应用 |
| US20250381150A1 (en) | 2024-03-08 | 2025-12-18 | Genzyme Corporation | Lipid nanoparticles |
| WO2026030375A2 (en) | 2024-07-30 | 2026-02-05 | Genzyme Corporation | Lipid nanoparticles and methods of manufacture and use thereof |
| CN118576568B (zh) * | 2024-08-06 | 2024-11-26 | 北京悦康科创医药科技股份有限公司 | 一种药物组合物及其制备方法和应用 |
| WO2026142951A1 (en) | 2024-12-23 | 2026-07-02 | Genzyme Corporation | Pharmaceutical system |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US6028077A (en) | 1997-04-15 | 2000-02-22 | Rinehart; Kenneth L. | Crambescidin compounds |
| CA2350882C (en) | 1998-11-12 | 2011-02-22 | Life Technologies Corporation | Transfection reagents |
| AU2002225878A1 (en) | 2000-11-02 | 2002-05-15 | Smith Kline Beecham Corporation | Receptor antagonist-lipid conjugates and delivery vehicles containing same |
| AU2002360762A1 (en) | 2001-12-19 | 2003-07-09 | Alza Corporation | Liposomal tumor necrosis factor compositions |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| US20130189364A1 (en) | 2004-07-09 | 2013-07-25 | Robert Sabin | Compositions and methods of potentiating adjuvant pharmaceuticals targeting latent viral infections |
| GB0418172D0 (en) | 2004-08-13 | 2004-09-15 | Ic Vec Ltd | Vector |
| WO2009111088A2 (en) * | 2008-01-02 | 2009-09-11 | The Johns Hopkins University | Antitumor immunization by liposomal delivery of vaccine to the spleen |
| US9029338B2 (en) * | 2009-08-14 | 2015-05-12 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| ES2702428T3 (es) | 2010-11-15 | 2019-02-28 | Life Technologies Corp | Reactivos de transfección que contienen amina y métodos para prepararlos y usarlos |
| KR20220025112A (ko) * | 2011-06-08 | 2022-03-03 | 샤이어 휴먼 지네틱 테라피즈 인크. | Mrna 전달을 위한 지질 나노입자 조성물 및 방법 |
| GR1008018B (el) | 2012-09-06 | 2013-10-29 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Λιπιδικα συμπλοκα αποτελουμενα απο ανιονικα λυσο-λιπιδια και η εφαρμογη αυτων |
| CN103296033B (zh) | 2013-05-28 | 2016-05-11 | 京东方科技集团股份有限公司 | 一种阵列基板及其制作方法 |
| JP2016528890A (ja) * | 2013-07-09 | 2016-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用 |
| CN113105559A (zh) | 2013-12-12 | 2021-07-13 | 生命技术公司 | 增强转染的膜穿透性肽和组合物以及其使用方法 |
| US10195280B2 (en) * | 2014-07-15 | 2019-02-05 | Life Technologies Corporation | Compositions and methods for efficient delivery of molecules to cells |
| RS64331B1 (sr) | 2015-06-19 | 2023-08-31 | Massachusetts Inst Technology | Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta |
| EP3315608B1 (en) * | 2015-06-26 | 2020-09-16 | Suzhou Ribo Life Science Co., Ltd. | Sirna, pharmaceutical composition and conjugate which contain sirna, and uses thereof |
| US10829787B2 (en) | 2015-10-14 | 2020-11-10 | Life Technologies Corporation | Ribonucleoprotein transfection agents |
| US11690921B2 (en) * | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
| GB2606038B (en) * | 2018-09-04 | 2023-05-03 | Univ Texas | Compositions and methods for organ specific delivery of nucleic acids |
-
2018
- 2018-07-17 WO PCT/US2018/042555 patent/WO2019045897A1/en not_active Ceased
- 2018-07-17 EP EP18749995.9A patent/EP3675826B1/en active Active
- 2018-07-17 JP JP2020512589A patent/JP7379325B2/ja active Active
- 2018-07-17 CA CA3073851A patent/CA3073851A1/en active Pending
- 2018-07-17 CN CN201880056879.8A patent/CN111065377A/zh active Pending
- 2018-07-17 US US16/038,107 patent/US20190060482A1/en not_active Abandoned
- 2018-07-17 AU AU2018324345A patent/AU2018324345B2/en active Active
- 2018-07-17 LT LTEPPCT/US2018/042555T patent/LT3675826T/lt unknown
-
2021
- 2021-07-16 US US17/378,466 patent/US12521447B2/en active Active
-
2023
- 2023-07-14 JP JP2023115742A patent/JP2023138526A/ja active Pending
-
2025
- 2025-12-10 US US19/415,525 patent/US20260108623A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019045897A1 (en) | 2019-03-07 |
| CN111065377A (zh) | 2020-04-24 |
| AU2018324345B2 (en) | 2024-06-27 |
| AU2018324345A1 (en) | 2020-03-05 |
| EP3675826B1 (en) | 2023-05-31 |
| JP2020532546A (ja) | 2020-11-12 |
| CA3073851A1 (en) | 2019-03-07 |
| JP2023138526A (ja) | 2023-10-02 |
| US20260108623A1 (en) | 2026-04-23 |
| US20220001023A1 (en) | 2022-01-06 |
| US12521447B2 (en) | 2026-01-13 |
| US20190060482A1 (en) | 2019-02-28 |
| JP7379325B2 (ja) | 2023-11-14 |
| EP3675826A1 (en) | 2020-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK4328309T3 (da) | Lipidsammensætning | |
| EP3981435A4 (en) | FAT COMPOSITION | |
| DK3835287T3 (da) | Kationisk lipid | |
| EP3534968A4 (en) | ANTI-BCMA T CAR LYMPHOCYTE COMPOSITIONS | |
| DK3733641T3 (da) | Kationiske lipider | |
| EP3582790A4 (en) | VERY POWERFUL IMMUNOGENIC COMPOSITIONS | |
| MA52546A (fr) | Compositions ciblées | |
| EP3432870A4 (en) | COMPOSITIONS WITH CHOLIN | |
| EP3558942C0 (en) | IONIZABLE CATIONIC LIPID FOR RNA ABSORPTION | |
| EP3694918A4 (en) | Aqueous binder compositions | |
| EP3606559C0 (en) | BIOORTHOGONAL COMPOSITIONS | |
| HUE049233T2 (hu) | C9ORF72-expresszió módosítására szolgáló készítmények | |
| DK3361870T3 (da) | Fungicidsammensætninger | |
| MA44702A (fr) | Compositions de suspension à libération prolongée | |
| DK3643350T3 (da) | Indføringskappe | |
| IL262574B (en) | Cationic lipid | |
| EP3297455A4 (en) | GLYCOSIDZUSAMMENSETZUNGEN | |
| DK3250182T3 (da) | Dispergible sammensætninger | |
| DK3334726T3 (da) | Plinabulinsammensætninger | |
| DK3253377T3 (da) | Monomethylfumarat-prodrug-sammensætninger | |
| EP3589716A4 (en) | ADHESION IMPROVEMENT COMPOSITIONS | |
| DK4234656T3 (da) | Sammensætninger | |
| EP3491382A4 (en) | OPTIMIZED INDIVIDUALIZED PREBIOTIC COMPOSITIONS | |
| DK3459354T3 (da) | Glyceridsammensætning | |
| DK3316857T3 (da) | Multifasiske sammensætninger |